Hantavirus is a fake, don't fall for it. Republishing Grand Princess Quarantine Orders FOIA, Part 2
________
Korea University and Moderna have been working on mRNA hantavirus vaccine since 2023
Korea University's Vaccine Innovation Center and US biotech firm Moderna (formerly ModeRNA Therapeutics), made world-famous by its multibillion-dollar Covid-19 vaccine profits.
By Brussels Signal | May 7, 2026
Korea University's Vaccine Innovation Center (VIC-K) and US biotech firm Moderna (formerly ModeRNA Therapeutics), made world-famous by its multibillion-dollar Covid-19 vaccine profits, have been jointly developing an mRNA-based hantavirus vaccine since signing a research and development agreement in September 2023, with the candidate now awaiting funding to begin human clinical trials.
A research team led by Professor Park Man-sung of Korea University College of Medicine's microbiology department confirmed in February 2025 that experimental doses prevented hantavirus infection in mice, according to Seoul Economic Daily.
Under the agreement, VIC-K provided Moderna with hantavirus antigen sequence information and Moderna in turn supplied the corresponding mRNA material, which the centre then used in antigen expression studies. The Korean partner had hosted an mRNA Access Partnership Seminar with Moderna on July 4, 2024 to set out the joint roadmap.
Hantavirus causes Haemorrhagic Fever with Renal Syndrome, marked by high fever, bleeding and kidney damage. Korea records 300 to 400 cases a year, mostly among young men in their twenties and thirties on military service, and the Korea Disease Control and Prevention Agency has placed the pathogen on its list of nine priority threats for future pandemic preparedness.
The World Health Organization has classified hantavirus as a possible "Disease X" pathogen. An older Korean inactivated vaccine, Hantavax, has been available since 1990 but offers limited long-term protection and does not cover hantavirus pulmonary syndrome strains found in the West.
Please go to Brussels Signal to continue reading.
Is it obscene enough?
The Silent Epidemic: Exposing vaccine lies, corporate greed and government betrayal
________
Korea University and Moderna have been working on mRNA hantavirus vaccine since 2023
Korea University's Vaccine Innovation Center and US biotech firm Moderna (formerly ModeRNA Therapeutics), made world-famous by its multibillion-dollar Covid-19 vaccine profits.
By Brussels Signal | May 7, 2026
Korea University's Vaccine Innovation Center (VIC-K) and US biotech firm Moderna (formerly ModeRNA Therapeutics), made world-famous by its multibillion-dollar Covid-19 vaccine profits, have been jointly developing an mRNA-based hantavirus vaccine since signing a research and development agreement in September 2023, with the candidate now awaiting funding to begin human clinical trials.
The deal was struck under Moderna's mRNA Access initiative, a programme that supplies preclinical mRNA vaccine candidates to academic teams working on emerging or neglected infectious diseases. The two sides had begun exploring possible collaboration as early as 2021.
A research team led by Professor Park Man-sung of Korea University College of Medicine's microbiology department confirmed in February 2025 that experimental doses prevented hantavirus infection in mice, according to Seoul Economic Daily.
Under the agreement, VIC-K provided Moderna with hantavirus antigen sequence information and Moderna in turn supplied the corresponding mRNA material, which the centre then used in antigen expression studies. The Korean partner had hosted an mRNA Access Partnership Seminar with Moderna on July 4, 2024 to set out the joint roadmap.
Hantavirus causes Haemorrhagic Fever with Renal Syndrome, marked by high fever, bleeding and kidney damage. Korea records 300 to 400 cases a year, mostly among young men in their twenties and thirties on military service, and the Korea Disease Control and Prevention Agency has placed the pathogen on its list of nine priority threats for future pandemic preparedness.
The World Health Organization has classified hantavirus as a possible "Disease X" pathogen. An older Korean inactivated vaccine, Hantavax, has been available since 1990 but offers limited long-term protection and does not cover hantavirus pulmonary syndrome strains found in the West.
Please go to Brussels Signal to continue reading.
________
Is it obscene enough?
The Silent Epidemic: Exposing vaccine lies, corporate greed and government betrayal
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.